What I want to illustrate in these posts is how large of a CDR-sb is typically expected in AD over a 2.5 year span.
From the previous quote, they said that high dose 150-150 44s in the extension to week 130 declined by ~1.0 CDR-sb points. Yet, we can see in these figures that a much larger decline typically occurs in AD. The first figure below is from a study of ~600 AD patients
so this is largish. Not sure, though, how many 44s were included.
All right when you magnify the first figure you find that at week 130 there was a typical decline of 2.6 CDR-sb points with
44s. The previously quoted figure with HT in the combined extension sample for the 44s was ~1.0.
This is starting to become interesting.
Here is the reference for the first figure below.https://www.nature.com/articles/nature24016/figures/12
Perhaps someone could check what the severity of these patients was.https://www.nature.com/articles/nature24016#Fig12
Hmm, some of these other figures are also interesting.
Some of them show that there are "fast" decliners; they mean fast.
For example below we see in mild AD those with high tau can decline by 8 CDR-SB at the 2 year point.
That is remarkably rapid.
Perhaps if Alzheon could genetically characterize a subgroup with super rapid decline, they might find
that their product worked especially well for them (possibly a subgroup within the 44s or others).
This is their whole strategy go precision medicine: It's a good idea. But why not take it to the next level?
Find another subgroup that has even better response than the 44s?https://www.youtube.com/watch?v=FU2C_ABZsaU
You do not have the required permissions to view the files attached to this post.